https://www.eileanther.com/publications daily 0.75 2025-12-17 https://www.eileanther.com/publications/eilean-therapeutics-advances-ze74-0282-a-highly-selective-inhibitor-of-mutated-jak2-v617f-into-first-in-human-clinical-development monthly 0.5 2025-12-17 https://www.eileanther.com/publications/eilean-therapeutics-presents-novel-selective-brain-permeable-cdk2-inhibitor-for-treatment-of-ccne1-dependent-cancers-jbdxd monthly 0.5 2025-12-17 https://www.eileanther.com/publications/eilean-therapeutics-presents-first-in-class-malt1-degrader-te205-demonstrating-in-vivo-efficacy-in-ulcerative-colitis-at-the-4th-international-conference-on-microbiology-and-immunology monthly 0.5 2025-11-06 https://www.eileanther.com/publications/eilean-therapeutics-presents-novel-selective-brain-permeable-cdk2-inhibitor-for-treatment-of-ccne1-dependent-cancers monthly 0.5 2025-11-06 https://www.eileanther.com/publications/eiiean-therapeutics-presents-novel-wild-type-sparing-reversible-pan-egfr-inhibitor-at-aacr-nci-eortc-international-conference monthly 0.5 2025-10-16 https://www.eileanther.com/publications/eilean-therapeutics-announces-upcoming-presentation-of-a-first-in-class-malt1-degrader-at-ash-annual-meeting monthly 0.5 2025-10-13 https://www.eileanther.com/publications/eilean-therapeutics-joins-the-leukemia-amp-lymphoma-societys-groundbreaking-beat-aml-master-clinical-trial monthly 0.5 2025-07-02 https://www.eileanther.com/publications/eilean-therapeutics-announces-fda-clearance-of-investigational-new-drug-ind-application-for-lomonitinib-for-the-treatment-of-acute-myeloid-leukemia-aml monthly 0.5 2025-07-02 https://www.eileanther.com/publications/eilean-therapeutics-receives-clearance-to-initate-rr-aml-trial-with-lomonitinib-a-selective-pan-flt3irak4-inhibitor monthly 0.5 2025-07-02 https://www.eileanther.com/publications/eilean-therapeutics-approved-to-initiate-first-patient-trial-with-balamenib-ze63-0302-a-selective-best-in-class-menin-inhibitor monthly 0.5 2025-07-02 https://www.eileanther.com/publications/eilean-therapeutics-acquires-best-in-class-non-clinical-ptpn2-program monthly 0.5 2025-07-02 https://www.eileanther.com/publications/eilean-therapeutics-initiates-first-in-human-trial-with-eiletoclax-a-selective-bcl2-inhibitor-with-limited-immune-suppression-and-improved-safety-compared-to-venetoclax-and-venetoclax-like-molecules monthly 0.5 2025-07-02 https://www.eileanther.com/publications/eilean-therapeutics-completes-single-dose-studies-and-initiates-multiple-dosing-of-healthy-volunteers-with-lomonitinib-a-selective-pan-flt3irak4-inhibitor monthly 0.5 2025-07-02 https://www.eileanther.com/publications/eilean-therapeutics-doses-first-patient-with-ze46-0134-a-selective-flt3wt-sparing-pan-flt3mut-inhibitor monthly 0.5 2024-08-05 https://images.squarespace-cdn.com/content/v1/6414aff8dc11d97de8311b64/1692912474784-J4XOOUBSASGKYJ72W7XK/image-asset.jpeg Press Releases - EILEAN THERAPEUTICS DOSES FIRST PATIENT WITH ZE46-0134, A SELECTIVE FLT3wt-SPARING, PAN FLT3mut INHIBITOR - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.eileanther.com/publications/category/press+releases monthly 0.5 https://www.eileanther.com/publications/category/publications monthly 0.5 https://www.eileanther.com/publications-1 daily 0.75 2026-01-09 https://www.eileanther.com/publications-1/ze74-0282-is-a-novel-jak2-jh2-domain-inhibitor-with-promising-preclinical-activity-in-jak2v617f-mutant-diseases monthly 0.5 2026-01-09 https://images.squarespace-cdn.com/content/v1/6414aff8dc11d97de8311b64/1767933013790-WD68183ONOCF2T950QVF/ZE74-0282+is+a+novel+JAK2+JH2+domain+inhibitor+with+promising+preclinical+activity+in+JAK2V617F+mutant+diseases Publications - ZE74-0282 is a novel JAK2 JH2 domain inhibitor with promising preclinical activity in JAK2V617F mutant diseases - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.eileanther.com/publications-1/discovery-of-a-novel-selective-brain-penetrant-cdk2-inhibitor-for-targeted-cancer-therapy monthly 0.5 2026-01-09 https://images.squarespace-cdn.com/content/v1/6414aff8dc11d97de8311b64/87b610fd-5129-4885-9a21-678bb2a678c7/Poster+CDK2+AACR_NCI_EORTC_Boston_102425.png Publications - Discovery of a novel, selective brain penetrant CDK2 inhibitor for targeted cancer therapy - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.eileanther.com/publications-1/a-novel-wild-type-sparing-pan-egfr-inhibitor-ze77-0273-with-broad-activity-against-resistance-mutations-in-egfr-mutant-nsclc monthly 0.5 2026-01-09 https://images.squarespace-cdn.com/content/v1/6414aff8dc11d97de8311b64/107d62dd-332e-422f-a6fe-34bf6aa0dff8/A+Novel%2C+wild-type+sparing+pan-EGFR+Inhibitor+%28ZE77-0273%29+with+Broad+Activity+Against+Resistance+Mutations+in+EGFR-Mutant+NSCLC Publications - A Novel, wild-type sparing pan-EGFR Inhibitor (ZE77-0273) with Broad Activity Against Resistance Mutations in EGFR-Mutant NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.eileanther.com/publications-1/a-novel-selective-bcl2-inhibitor-with-limited-immune-suppression-and-improved-safety-compared-to-venetoclax monthly 0.5 2026-01-09 https://images.squarespace-cdn.com/content/v1/6414aff8dc11d97de8311b64/48177e4e-d1b9-4cc6-913b-30bb9c643fef/A+novel+Selective+BCL2+inhibitor+with+limited+immune+suppression+and+improved+safety+compared+to+venetoclax.png Publications - A novel Selective BCL2 inhibitor with limited immune suppression and improved safety compared to venetoclax - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.eileanther.com/publications-1/therapeutic-targeting-of-flt3-gate-keeper-mutation-with-e2082-0047-in-traditional-and-a-novel-immunocompetent-murine-adoptive-transfer-model-of-aml monthly 0.5 2025-12-22 https://images.squarespace-cdn.com/content/v1/6414aff8dc11d97de8311b64/5bedbde5-7365-4fdf-a2c8-f1ea8dcb6175/Therapeutic+Targeting+of+FLT3+gate+keeper+mutation+with+E2082-0047+in+traditional+and+a+novel+Immunocompetent+murine+adoptive+transfer+model+of+AML Publications - Therapeutic Targeting of FLT3 gate keeper mutation with E2082-0047 in traditional and a novel Immunocompetent murine adoptive transfer model of AML - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.eileanther.com/publications-1/ash2022-a-novel-inhibitor-of-flt3-and-its-drug-resistant-mutants-with-superior-activity-to-gilteritinib-in-molm-13-preclinical-acute-myeloid-leukemia-xenograft-model monthly 0.5 2025-12-22 https://images.squarespace-cdn.com/content/v1/6414aff8dc11d97de8311b64/9a2e607c-1a42-474d-b2f6-5176afc40afa/ASH2022+A+Novel+Inhibitor+of+FLT3+and+its+Drug-resistant+Mutants+with+Superior+Activity+to+Gilteritinib+in+MOLM-13+Preclinical+Acute+Myeloid+Leukemia+Xenograft+Model.png Publications - ASH2022: A Novel Inhibitor of FLT3 and its Drug-resistant Mutants with Superior Activity to Gilteritinib in MOLM-13 Preclinical Acute Myeloid Leukemia Xenograft Model - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.eileanther.com/home daily 1.0 2026-01-06 https://images.squarespace-cdn.com/content/v1/6414aff8dc11d97de8311b64/1760607333652-895N5KBZWDU1ARLLDQ8A/Eilean+Therapeutics+Presents+Novel%2C+Selective%2C+Brain-Permeable+CDK2+Inhibitor+for+Treatment+of+CCNE1-Dependent+Cancers https://images.squarespace-cdn.com/content/v1/6414aff8dc11d97de8311b64/1760385257142-7S0UTZQK3WC6RSG1HLWC/aacr.jpg https://www.eileanther.com/about daily 0.75 2024-01-08 https://images.squarespace-cdn.com/content/v1/6414aff8dc11d97de8311b64/d8d45a0a-9507-45be-ae74-a3d2d1f0cb99/2+%287%29.png https://images.squarespace-cdn.com/content/v1/6414aff8dc11d97de8311b64/7f7b11fb-cacc-4695-b62f-0782e6a62721/Add+a+heading+%283%29.png https://www.eileanther.com/contact daily 0.75 2024-12-30 https://www.eileanther.com/approach daily 0.75 2023-08-20 https://images.squarespace-cdn.com/content/v1/6414aff8dc11d97de8311b64/beb2c5e7-cb17-4f33-b9dd-c282027a5e1b/3+%287%29.png https://www.eileanther.com/pipeline daily 0.75 2025-12-22 https://www.eileanther.com/management-team daily 0.75 2025-03-14 https://images.squarespace-cdn.com/content/v1/6414aff8dc11d97de8311b64/f5a49208-988c-4401-b82b-4bc2a0100d4e/Untitled+design+%286%29.png Leadership 2 https://images.squarespace-cdn.com/content/v1/6414aff8dc11d97de8311b64/65b0e278-ac63-4d80-aba6-eeccece1d7c9/Untitled+design+%287%29.png Leadership 2 https://images.squarespace-cdn.com/content/v1/6414aff8dc11d97de8311b64/fb30b238-e1b0-4ebf-8c1c-4ab27d2d9429/6+%286%29.png Leadership 2 https://images.squarespace-cdn.com/content/v1/6414aff8dc11d97de8311b64/5b33bae6-909f-40dd-a9cb-c1ef385d69af/7+%285%29.png Leadership 2 https://images.squarespace-cdn.com/content/v1/6414aff8dc11d97de8311b64/a29d970c-57ec-4bd6-b4ee-74afc5d6976b/Untitled+design+%285%29.png Leadership 2 https://images.squarespace-cdn.com/content/v1/6414aff8dc11d97de8311b64/f6377006-279f-4010-96db-5fae65de4b96/Untitled+design+%2879%29.png Leadership 2 https://www.eileanther.com/sab daily 0.75 2024-12-04 https://images.squarespace-cdn.com/content/v1/6414aff8dc11d97de8311b64/a471b29c-19ae-4849-b01d-33a94db09677/8+%283%29.png Scientific Advisory Board https://images.squarespace-cdn.com/content/v1/6414aff8dc11d97de8311b64/281e3c85-d459-4d32-ae0c-5768b07b3599/11+%282%29.png Scientific Advisory Board https://www.eileanther.com/board-of-directors daily 0.75 2024-05-13 https://images.squarespace-cdn.com/content/v1/6414aff8dc11d97de8311b64/f5a49208-988c-4401-b82b-4bc2a0100d4e/Untitled+design+%286%29.png Board of Directors https://images.squarespace-cdn.com/content/v1/6414aff8dc11d97de8311b64/8e9bc6b5-eb29-452f-9787-ac26ec1f1538/3.png Board of Directors https://images.squarespace-cdn.com/content/v1/6414aff8dc11d97de8311b64/3ca54972-f98c-4b3a-a006-66453ed09e1c/10+%283%29.png Board of Directors https://images.squarespace-cdn.com/content/v1/6414aff8dc11d97de8311b64/2a3eed50-d60d-4952-bb85-cd280f0f2990/Untitled+design+%2880%29.png Board of Directors